Ari Rosenberg
University of Chicago · University of Chicago Medicine Comprehensive Cancer Center · University of Chicago - Comprehensive Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ari Rosenberg as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:41 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07768189 · A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell CarcinomaCorbus Pharmaceuticals Inc. · recruiting · Oropharyngeal Carcinoma (OPC) · study chair
- Ph2NCT07290621 · Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat CancerUniversity of Chicago · recruiting · Oropharyngeal Cancer · principal investigator
- Ph2NCT07179315 · A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After TreatmentUniversity of Chicago · recruiting · Head and Neck Cancer · study chair
- Ph1NCT06912087 · Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCCUniversity of Chicago · recruiting · Head and Neck Neoplasms, Carcinoma, Squamous Cell, Neoplasm Recurrence, Local · principal investigator
- Ph1/Ph2NCT06265727 · A Phase 1/2 Study to Investigate CRB-701 in Solid TumorsCorbus Pharmaceuticals Inc. · recruiting · Solid Tumor, Adult · principal investigator
- Ph1NCT06110195 · Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck CancerUniversity of Chicago · terminated · Head and Neck Cancer, Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck · principal investigator
- Ph1NCT06005324 · Personalized, Adaptive Treatment for Locally Advanced Head and Neck CancerUniversity of Chicago · recruiting · HPV-Negative Squamous Cell Carcinoma · principal investigator
- Ph1NCT05526924 · Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck CancerUniversity of Chicago · recruiting · Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma · principal investigator
- Ph2NCT05420948 · A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck CancerUniversity of Chicago · recruiting · Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Neoplasms · principal investigator
- Ph1/Ph2NCT05108870 · TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck CancersUniversity of Chicago · active not recruiting · Human Papilloma Virus, HPV, HPV Positive Oropharyngeal Squamous Cell Carcinoma · principal investigator
- Ph1NCT04572100 · Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal CancerUniversity of Chicago · completed · Oropharyngeal Squamous Cell Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:41 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 5 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Deciphering the mechanism of response to novel HPV-specific viral immune therapy in HPV associated head and neck cancerR21DE034942 · NIDCR · UNIVERSITY OF CHICAGO · fiscal years 2025 · $451,000 awarded in 2025Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:41 UTC. The ranking covers the 200 most relevant of 128 PubMed records, and a shared surname and initials can bring in a namesake. All 128 on PubMed
- 1,469 citationsRCR 61.5
- Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.J Immunother · 2013956 citationsRCR 23.3
- 407 citationsRCR 8.7
- Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial.Lancet Oncol · 2019334 citationsRCR 12.1
- Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.Mol Genet Metab · 2010317 citationsRCR 9.0
- Multidomain lifestyle intervention benefits a large elderly population at risk for cognitive decline and dementia regardless of baseline characteristics: The FINGER trial.Alzheimers Dement · 2018316 citationsRCR 15.5
- 271 citationsRCR 9.9
- Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas.Int J Radiat Oncol Biol Phys · 2003232 citationsRCR 5.9
- 232 citationsRCR 10.3
- Symptoms and Distress in Children With Advanced Cancer: Prospective Patient-Reported Outcomes From the PediQUEST Study.J Clin Oncol · 2015225 citationsRCR 10.5